Pancreatic cancer: Utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy

Radiology

Volumn 256, Issue 2, 2010, Pages 441-449

  Akisik, M Fatih ^a   Sandrasegaran, Kumaresan ^a   Bu, Guixue ^a   Lin, Chen ^a   Hutchins, Gary D ^a   Chiorean, Elena G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GEMCITABINE; SORAFENIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ABDOMINAL AORTA; ANTIANGIOGENIC ACTIVITY; ARTERIAL BLOOD; ARTICLE; CONTRAST ENHANCEMENT; KINETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIAGNOSTIC USE; FEMALE; HUMAN; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PYRIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77955127559     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091733     Document Type: Article

References (71)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4 ): 225-249.
2. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg 1999;36(2 ): 59-152.
3. Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 2006;17(2):189-199. (Pubitemid 43160105)
4. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035-1046.
5. Burris H 3rd, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008;13(3):289-298. (Pubitemid 351679904)
6. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616-623.
7. Verweij J, Therasse P, Eisenhauer E;RECIST working group. Cancer clinical trial outcomes: any progress in tumour-size assessment? Eur J Cancer 2009;45(2):225-227.
8. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248(3):894-900.
9. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2):466-473.
10. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007;188(4):1001-1008. (Pubitemid 46496932)
11. Hsiang DJ, Yamamoto M, Mehta RS, et al. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 2007;142(9):855-861; discussion 860-861.
12. Esserman L, Hylton N, George T, Weidner N. Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 1999;5(1):13-21. (Pubitemid 29108803)
13. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18(4):467-477.
14. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-777.
15. Yamashita Y, Baba T, Baba Y, et al. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy. Radiology 2000;216(3):803-809. (Pubitemid 30660858)
16. Hawighorst H, Weikel W, Knapstein PG, et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998;4(10):2305-2312. (Pubitemid 28477893)
17. Mayr NA, Yuh WT, Arnholt JC, et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 2000;12(6):1027-1033.
18. de Lussanet QG, Backes WH, Griffioen AW, et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005;63(5):1309-1315.
19. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003;56(4):958-965. (Pubitemid 36794026)
20. Atkin G, Taylor NJ, Daley FM, et al. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. Br J Surg 2006;93(8):992-1000.
21. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007;63(3):335-350. (Pubitemid 47321040)
22. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(2):425-430.
23. Lall CG, Howard TJ, Skandarajah A, DeWitt JM, Aisen AM, Sandrasegaran K. New con cepts in staging and treatment of locally advanced pancreatic head cancer. AJR Am J Roentgenol 2007;189(5):1044-1050. (Pubitemid 350032986)
24. Tamm EP, Silverman PM, Charnsangavej C, Evans DB. Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol 2003;180(5):1311-1323. (Pubitemid 36504620)
25. O'Malley ME, Boland GW, Wood BJ, Fernandez-del Castillo C, Warshaw AL, Mueller PR. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. AJR Am J Roentgenol 1999;173(6):1513-1518.
26. Dal Lago L, D'Hondt V, Awada A. Se lected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008;13(8):845-858.
27. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40(11):715-724. (Pubitemid 41546838)
28. Materne R, Smith AM, Peeters F, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 2002;47(1):135-142. (Pubitemid 34019702)
29. Medved M, Karczmar G, Yang C, et al. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: variability and changes in tumor tissue over time. J Magn Reson Imaging 2004;20(1):122-128.
30. Michaely HJ, Kramer H, Oesingmann N, Lodemann KP, Reiser MF, Schoenberg SO. Semiquantitative assessment of first-pass renal perfusion at 1.5 T: comparison of 2D saturation recovery sequences with and without parallel imaging. AJR Am J Roentgenol 2007;188(4):919-926.
31. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7(1):91-101.
32. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrastenhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17(5):509-520.
33. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24(20):3293-3298. (Pubitemid 46622069)
34. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3):223-232.
35. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
36. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005;30(3):324-341.
37. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21(21):3955-3964.
38. Miyazaki K, Collins DJ, Walker-Samuel S, et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008;18(7):1414-1421.
39. van Laarhoven HW, Rijpkema M, Punt CJ, et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 2003;18(3):315-320.
40. Wang B, Gao ZQ, Yan X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol 2005;46(4):353-358.
41. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7(4):496-501.
42. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13(2 pt 2):770s-776s.
43. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5(10):835-844. (Pubitemid 44480537)
44. Parker GJ, Suckling J, Tanner SF, et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7(3):564-574. (Pubitemid 28360876)
45. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratifi cation of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009;250(1):110-117.
46. Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(24):3995-4000.
47. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007;370(9605):2071-2073. (Pubitemid 350296281)
48. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77(2):325-328.
49. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82(5):1013-1016. (Pubitemid 30128852)
50. Ishii H, Okada S, Sato T, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997;44(13):279-283. (Pubitemid 27096053)
51. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005;93(2):195-199. (Pubitemid 41133205)
52. Nakai Y, Kawabe T, Isayama H, et al. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008;75(1-2):120-126.
53. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32(1):35-41.
54. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003;26(5):462-467.
55. Ziske C, Schlie C, Gorschlüter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89(8):1413-1417. (Pubitemid 37386593)
56. Goulart BH, Clark JW, Lauwers GY, et al. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol 2009;2:13.
57. Huang PI, Chao Y, Li CP, et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2009;73(1):159-165.
58. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005;93(7):740-743. (Pubitemid 41486431)
59. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9(2):132-138.
60. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009;115(12):2630-2639.
61. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004;67(2):93-97. (Pubitemid 39482675)
62. Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005;104(6):1237-1245.
63. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 2006;24(3):379-385.
64. Lee J, Park JO, Kim WS, et al. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 2004;66(1):32-37.
65. Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101(1):133-138. (Pubitemid 38812432)
66. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92(3):569-577.
67. Pino MS, Milella M, Gelibter A, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009;76(4):254-261.
68. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20(5):1182-1191.
69. Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001;60(4):316-321.
70. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95(5):587-592.
71. Recommendations for MR measurement methods at 1.5-Tesla and endpoints for use in Phase 1/2a trials of anti-cancer therapeutics affecting tumor vascular function. National Cancer Institute. http://imaging.cancer.gov/images/Documents/ 14a39040-dad1-46f8-bf88-bae2e7401ebe/DCE-RecommendationfromNov2004NCIWorkshop(2) .pdf. Published 2004. Accessed July 7, 2009.